Any period changes are typically related to the metabolic effects of weight loss rather than direct drug action on reproductive tissues
Further clinical trials are warranted to validate these findings, clarify underlying mechanisms, and assess long-term safety, ultimately paving the way for novel treatment approaches in rheumatology
[54] Society and culture [edit] Legal status [edit] The US Food and Drug Administration (FDA) granted the application for tirzepatide priority review designation
Instead, GLP-1 microdosing embraces the principle of finding the minimum effective dose that achieves desired health outcomes
The goal is calming the chronic inflammation that drives autoimmune disease
Onuma H, Inukai K, Kitahara A, Moriya R, Nishida S, Tanaka T, et al